Sabbin Hanyoyi masu Alkawari kan Ingantattun Magungunan Ciwon daji

LUMICKS, wani kamfani na kayan aikin kimiyyar rayuwa wanda ke haɓaka kayan aiki don haɓakar ƙwayoyin ƙwayoyin cuta guda ɗaya da bincike na ƙwayoyin cuta, a yau sun sanar da cewa an buga wata takarda da ke buɗe sabbin bayanai game da aikin Chimeric Antigen Receptor (CAR) T a cikin fitowar Fabrairu 2022 na Frontiers in Immunology. Takardar ta bayyana sabbin binciken da aka gudanar a Kwalejin Kings London karkashin kulawar Dokta John Maher, tare da hadin gwiwar Leucid Bio, ta hanyar amfani da LUMICKS' z-Movi® Cell Avidity Analyzer. Wannan sabon bincike ya nuna cewa ƙara mai karɓa na biyu da aka yi niyya zuwa ƙwayoyin CAR T yana haɓaka ikon su na kai hari ga ƙwayoyin cutar kansa kuma yana nuna alƙawarin inganta rigakafi don ciwon daji a cikin samfuran pre-na asibiti.

Dokta John Maher, Babban Malami a Kwalejin Kings London a Makarantar Ciwon daji & Kimiyyar Magunguna, kuma Babban Jami'in Kimiyya na Leucid Bio, ya ce, "Babban iyawa na z-Movi Cell Avidity Analyzer ya ba mu damar auna jimlar ƙarfin hulɗar. tsakanin rukunin mu na ƙwayoyin CAR T da ƙwayoyin kansa. Yin amfani da kayan aikin LUMICKS'z-Movi, cikin sauƙi zamu iya nemo motocin 'goldilocks' waɗanda ba su ɗaure da ƙarfi ko rauni ga sel waɗanda aka yi niyya kuma suna nuna mafi girman kisa a cikin ƙirar asibiti. Sabbin fahimtar da aka samu ta amfani da ma'aunin avidity na cell na iya taimakawa da gaske inganta yadda muke tsara hanyoyin kwantar da tarzoma."

Andrea Candelli, Babban Jami'in Kimiyya na LUMICKS, "Muna raba farin cikin ƙungiyar Kings College game da ƙarin shaidun da wannan takarda ta nuna na muhimmiyar rawar da ƙwayar salula ke takawa wajen ganowa da inganta ƙwayoyin CAR T. Binciken da Dr. Maher ya yi mai karfi ya jaddada fahimtar cewa fasaharmu ta juyin juya hali za ta iya taimaka wa masu bincike a duniya su gano, da kuma taimaka wa kimiyya da kyau wajen magance manyan kalubalen da ke tattare da lafiyar dan Adam, musamman wajen kera magungunan rigakafi masu inganci don yakar cutar kansa."

CAR-T cell immunotherapies canza kwayoyin T a cikin tsarin rigakafi don manufa da lalata kwayoyin cutar kansa ta hanyar sake tsara kwayoyin halittar T don yin furotin na CAR, wanda kwayoyin T ke ɗaure, da kuma kai hari, kwayoyin cutar kansa. Ana ba da irin waɗannan hanyoyin kwantar da hankali azaman jiyya ga wasu cututtukan daji kuma masu bincike da yawa, gami da Dr.

Z-Movi yana auna sha'awa, ko matakin ɗaure, tsakanin ƙwayoyin rigakafi kamar CAR Ts, da maƙasudin su, ƙwayoyin cutar kansa, yana ba masu bincike damar gano sel masu tasirin immunotherapeutic mafi ƙarfi a matsayin 'yan takara don yin hari da lalata takamaiman ƙwayoyin cutar kansa. Wannan sabuwar fasaha tana ba da tsinkaya, mai iya sakewa, da kuma sakamako mai sauri a ƙudurin tantanin halitta guda ɗaya ba tare da ɓata ingancin tantanin halitta ba, kuma yana tabbatar da amintaccen sarrafa samfurin. LUMICKS'Maganin kyamar kwayar halitta suna amfani da acoustics don auna ƙarfi da hulɗar tsakanin sel, tare da manufar rage yanayin ci gaban ƙwayoyi don hanyoyin kwantar da ƙwayoyin ƙwayoyin cuta da sauran magungunan rigakafi da rage ƙimar gazawa a cikin gwaji na asibiti. Da farko an gabatar da shi a cikin 2020, z-Movi ya sami jan hankali sosai a cikin dakunan gwaje-gwaje na ilimi da biopharma a duniya, tare da haɓaka tallace-tallace cikin sauri a cikin 2021.